1. Home
  2. CRSP vs HBM Comparison

CRSP vs HBM Comparison

Compare CRSP & HBM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CRSP
  • HBM
  • Stock Information
  • Founded
  • CRSP 2013
  • HBM 1927
  • Country
  • CRSP Switzerland
  • HBM Canada
  • Employees
  • CRSP 393
  • HBM N/A
  • Industry
  • CRSP Biotechnology: Biological Products (No Diagnostic Substances)
  • HBM Metal Mining
  • Sector
  • CRSP Health Care
  • HBM Basic Materials
  • Exchange
  • CRSP Nasdaq
  • HBM Nasdaq
  • Market Cap
  • CRSP 3.3B
  • HBM 2.9B
  • IPO Year
  • CRSP 2016
  • HBM N/A
  • Fundamental
  • Price
  • CRSP $35.62
  • HBM $7.69
  • Analyst Decision
  • CRSP Buy
  • HBM Hold
  • Analyst Count
  • CRSP 17
  • HBM 1
  • Target Price
  • CRSP $74.53
  • HBM $14.00
  • AVG Volume (30 Days)
  • CRSP 2.0M
  • HBM 5.6M
  • Earning Date
  • CRSP 05-06-2025
  • HBM 05-12-2025
  • Dividend Yield
  • CRSP N/A
  • HBM 0.19%
  • EPS Growth
  • CRSP N/A
  • HBM N/A
  • EPS
  • CRSP N/A
  • HBM 0.20
  • Revenue
  • CRSP $37,675,000.00
  • HBM $2,021,200,000.00
  • Revenue This Year
  • CRSP $51.35
  • HBM $8.05
  • Revenue Next Year
  • CRSP $282.16
  • HBM $0.87
  • P/E Ratio
  • CRSP N/A
  • HBM $38.45
  • Revenue Growth
  • CRSP N/A
  • HBM 19.60
  • 52 Week Low
  • CRSP $30.04
  • HBM $5.95
  • 52 Week High
  • CRSP $67.88
  • HBM $10.49
  • Technical
  • Relative Strength Index (RSI)
  • CRSP 44.74
  • HBM 56.82
  • Support Level
  • CRSP $33.03
  • HBM $6.98
  • Resistance Level
  • CRSP $39.38
  • HBM $7.70
  • Average True Range (ATR)
  • CRSP 1.81
  • HBM 0.23
  • MACD
  • CRSP -0.19
  • HBM 0.06
  • Stochastic Oscillator
  • CRSP 33.64
  • HBM 90.78

About CRSP CRISPR Therapeutics AG

Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.

About HBM Hudbay Minerals Inc. (Canada)

Hudbay Minerals Inc is a Canadian mining company with its operations, property developments, and exploration activities across the United States. The mines that Hudbay operates are located in Manitoba, Canada, Arizona, United States; and Peru. The company is principally focused on the discovery, production, and marketing of base and precious metals. Hudbay produces copper concentrate, which contains copper, gold, and silver, as well as zinc metal. More than half the company's revenue is attributable to the copper business. The company sells copper concentrates to smelters across Asia, America, and Europe, and sells Zinc metal, another source of revenue, to industrial customers across North America.

Share on Social Networks: